Bard gets FDA nod for vascular stent

Interventional technology developer C. R. Bard of Murray Hill, NJ, has received U.S. Food and Drug Administration (FDA) clearance to market its E-Luminexx vascular stent.

Designed for the treatment of patients with common or external iliac artery occlusive disease, E-Luminexx is a flexible, self-expanding nitinol stent. It will be marketed by Bard's peripheral vascular division in Tempe, AZ.

Related Reading

Bard boosts sales in Q2, July 24, 2008

Bard posts Q4 results, February 1, 2008

Bard signs Howard, March 13, 2007

Bard closes Venetec deal, April 10, 2006

Bard bids for Venetec, March 2, 2006

Copyright © 2008 AuntMinnie.com

Page 1 of 181
Next Page